electroCore, Inc. Common Stock (ECOR)
electroCore, Inc. is a biotechnology company focused on developing non-invasive neuromodulation therapies. Known for their FDA-approved device, gammaCore, they aim to treat various conditions such as migraines and cluster headaches through its innovative vagus nerve stimulation technology.
Company News
electroCore announced Peter Cuneo's departure from the Board of Directors and elected Thomas J. Errico, MD as the new Chairman, effective September 2, 2025. Cuneo will continue as a strategic advisor to the company.
The average of price targets set by Wall Street analysts indicates a potential upside of 251.8% in electroCore (ECOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The Dow Jones closed lower by over 60 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider trans...
Analysts say these are penny stocks to buy but do you agree? The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 1,050% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.